4//SEC Filing
O'Connell Joseph P 4
Accession 0001209191-20-062691
CIK 0001717452other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 4:06 PM ET
Size
9.4 KB
Accession
0001209191-20-062691
Insider Transaction Report
Form 4
O'Connell Joseph P
Chief Medical Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2020-12-08+60,373→ 60,373 totalExercise: $16.52Exp: 2030-12-08→ Common Stock (60,373 underlying)
Footnotes (1)
- [F1]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
Issuer
Odonate Therapeutics, Inc.
CIK 0001717452
Entity typeother
Related Parties
1- filerCIK 0001723966
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 4:06 PM ET
- Size
- 9.4 KB